Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback